<p><strong>We are pleased to invite you to our upcoming free online webinar on June 11, 2026 focused on one of the most pressing challenges in environmental monitoring and water quality management — PFAS (Per- and Polyfluoroalkyl Substances).</strong></p><p>As regulatory frameworks continue to evolve and compliance deadlines approach, laboratories, water utilities, and environmental professionals need robust, reliable, and cutting-edge analytical solutions to stay ahead.</p><blockquote><p class="cke-user_style-important"><strong>👉</strong><a target="_blank" rel="noopener noreferrer" href="https://events.teams.microsoft.com/event/91d97003-fe33-4dca-b80b-160d9f8a5655@485ca04e-6f74-4050-9764-cdb4bfa89c25"><strong>Registration HERE</strong></a></p></blockquote><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/ALS_analyzy_PFAS_a9e4a87fbc.jpg" alt="ALS: Advanced PFAS Analytical Services " srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_ALS_analyzy_PFAS_a9e4a87fbc.jpg 245w," sizes="100vw" width="600" height="336"></p><h4><strong>🎤 Our Speaker</strong></h4><p>The webinar will be hosted by <strong>Jana Kováčová, Ph.D., PFAS Regional Lead for Continental Europe Environmental Division</strong>, who has dedicated the last several years to the field of PFAS analysis and determination in ALS laboratories. Jana is a recognized expert in PFAS environmental analytics and will share practical insights and the latest developments in analytical strategies to help your organization achieve and maintain compliance.</p><h4><strong>🎯 What You Will Learn</strong></h4><ul><li>Latest <strong>regulatory developments</strong> and compliance requirements for PFAS in water, including <strong>EU Drinking Water Directive 2020/2184</strong> and its implications for water suppliers and laboratories.</li><li><strong>Regulatory updates for surface water and groundwater</strong> — what's new and what to expect next.</li><li>Overview of <strong>advanced analytical strategies</strong> for PFAS detection and quantification in water matrices and how we analyse PFAS samples.</li><li>Key <strong>analytical challenges</strong> associated with PFAS testing — from ultra-trace detection to matrix interferences and contamination control.</li><li>The critical importance of using tested <strong>sampling containers</strong> and sample preservation to ensure reliable results.</li><li>Illustrative <strong>examples of results</strong> from real-world PFAS water analyses.</li><li>How ALS can support your needs with <strong>accredited PFAS testing services</strong>.</li></ul><h4><strong>👥 Who Should Attend</strong></h4><p>This webinar is designed for our clients, professionals, laboratory and technical staff, scientists, as well as anyone with an interest in analytical chemistry who wants to better understand the occurrence of these "forever chemicals" in the environment. &nbsp;</p><h4><strong>💬 Q&amp;A Session</strong></h4><p>There will be a live Q&amp;A session at the end of the webinar. You are welcome to submit your questions in advance during registration or ask them live on the day.</p><h4><strong>📅 Additional Webinar Info:</strong></h4><ul><li><strong>Platform: </strong>Microsoft Teams (online)</li><li><strong>Time: </strong>10:00 CEST</li><li><strong>Language: </strong>English</li><li><strong>Duration:</strong> approx. 45 - 60 minutes (incl. Q&amp;A)<br>Extras: If you are unable to attend on the day, please register and we will provide you with the recording of the webinar.</li></ul><h4><strong>🔬 About ALS Environmental</strong></h4><p>ALS is a global leader in environmental testing and analytical services, providing accredited PFAS analysis to clients across Europe and beyond. Our dedicated PFAS experts help clients navigate the complex regulatory landscape with confidence.</p><blockquote><p>For further information, please contact us on: <strong>marketing.cz@alsglobal.com</strong></p></blockquote><p>We look forward to welcoming you to this important discussion on PFAS compliance in water.</p>

Invitation to the ALS Webinar PFAS in Water 2026: Achieving Compliance through Advanced Analytical Strategies

<p><strong>Cells in the human body constantly evaluate signals from their surroundings and decide whether to divide, grow, or remain inactive. One of the key systems controlling this communication is the so-called Wnt signalling pathway. If this mechanism becomes disrupted, cells can spiral out of control, leading to uncontrolled growth and the development of tumours. Scientists from CEITEC and the Faculty of Science at Masaryk University have now described a critical decision-making process – the point at which a cell’s future development is decided. Their findings may, in the future, contribute to the search for ways to slow down or stop such processes in diseases like cancer.</strong></p><p>The <strong>Wnt signalling pathway</strong> is a mechanism that coordinates billions of cells in the body – it is responsible for the development of an entire organism from a single cell, and it continues to regulate tissue renewal throughout adult life. Until now, it was not fully understood how this mechanism works in detail. However, new research by teams from Masaryk University (MUNI) shows that the cells do not respond to stimuli smoothly, but rather operate in an on-off mode once a certain decision-threshold is crossed. This principle changes our understanding of how cells function together and helps explain situations in which cellular decision-making goes out of control and may lead to cancer development.</p><p>The process begins at the surface of the cell, where a signal is captured by a receptor embedded in the cell membrane. A protein called Dishevelled (DVL) then binds to this receptor and carries the signal further into the cell. However, for the signal to continue, DVL must first undergo a series of chemical modifications. Small chemical groups begin to accumulate on its surface, progressively increasing its negative charge.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/CEITEC_Vedci_nasli_bod_zlomu_v_bunce_Prave_takto_muze_zacit_rakovina_4_7c8f80376d.jpg" alt="CEITEC/Tripsianes Lab: Scientists Uncover a Tipping Point in Cells. This Is How Cancer May Begin: New mechanism of Wnt signal transduction " srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_CEITEC_Vedci_nasli_bod_zlomu_v_bunce_Prave_takto_muze_zacit_rakovina_4_7c8f80376d.jpg 245w," sizes="100vw" width="1600" height="604"></p><p>And this is where the<strong> decisive moment occurs</strong>.</p><p><i>“We found that the DVL protein behaves like a switch – its structure changes abruptly once the negative charge on its surface exceeds a certain threshold. Only then does it rearrange and allow the signal to proceed further,”</i> explains first author <a target="_blank" rel="noopener noreferrer" href="https://www.ceitec.eu/miroslav-micka/u92423?page=publication"><strong>Miroslav Micka</strong></a>.</p><p>At this point, DVL detaches from the receptor, allowing the signal to move deeper into the cell. The cell then receives a clear instruction on how to respond – for example, to start dividing or change its function.</p><p>This crucial “tipping point,” where the fate of the signal is decided, has so far been only partially understood: <i>“Scientists knew the pathway the signal follows, but they mostly viewed it as a gradual regulatory system. However, our teams have shown that it is rather a process based on decision points and abrupt changes once a certain threshold is crossed. This is important not only for understanding how cells function, but also for explaining what happens when these processes become dysregulated,”</i> add corresponding authors <a target="_blank" rel="noopener noreferrer" href="https://www.ceitec.eu/konstantinos-tripsianes-ph-d/u17552?page=publication"><strong>Konstantinos Tripsianes</strong></a><strong> from CEITEC MUNI</strong> and <a target="_blank" rel="noopener noreferrer" href="https://www.muni.cz/en/people/11088-vitezslav-bryja"><strong>Vítězslav Bryja</strong></a><strong> from the Faculty of Science</strong>.</p><p>Such decision points in cellular signalling are particularly important from a medical perspective, as their disruption can trigger processes that lead to tumour development. A better understanding of these processes, on the other hand, paves the way for more effective treatments.</p><p>The study was published in the journal <a target="_blank" rel="noopener noreferrer" href="https://www.science.org/doi/10.1126/sciadv.aed8899"><strong>Science Advances</strong></a>.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/CEITEC_Vedci_nasli_bod_zlomu_v_bunce_Prave_takto_muze_zacit_rakovina_2_af629ac80a.jpg" alt="CEITEC/Tripsianes Lab: Scientists Uncover a Tipping Point in Cells. This Is How Cancer May Begin: DVL in a cell (green), cell nucleus (blue)" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_CEITEC_Vedci_nasli_bod_zlomu_v_bunce_Prave_takto_muze_zacit_rakovina_2_af629ac80a.jpg 156w," sizes="100vw" width="1600" height="1600"><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/CEITEC_Vedci_nasli_bod_zlomu_v_bunce_Prave_takto_muze_zacit_rakovina_36bfbfa0c6.jpg" alt="CEITEC/Tripsianes Lab: Scientists Uncover a Tipping Point in Cells. This Is How Cancer May Begin: DVL in a cell (green), enzym modifiyng DVL (red), cell nucleus (blue)" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_CEITEC_Vedci_nasli_bod_zlomu_v_bunce_Prave_takto_muze_zacit_rakovina_36bfbfa0c6.jpg 156w," sizes="100vw" width="1600" height="1600"><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/CEITEC_Vedci_nasli_bod_zlomu_v_bunce_Prave_takto_muze_zacit_rakovina_3_f21d18e3ca.jpg" alt="CEITEC/Tripsianes Lab: Scientists Uncover a Tipping Point in Cells. This Is How Cancer May Begin: DVL in a cell (green), enzym modifiyng DVL (red), cell nucleus (blue)" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_CEITEC_Vedci_nasli_bod_zlomu_v_bunce_Prave_takto_muze_zacit_rakovina_3_f21d18e3ca.jpg 156w," sizes="100vw" width="1600" height="1600"></p><p>&nbsp;</p><blockquote><h4><strong>Original article</strong></h4><h4><a target="_blank" rel="noopener noreferrer" href="https://www.science.org/doi/10.1126/sciadv.aed8899"><strong>A Wnt-induced conformational phospho-switch in DVL3 controls association with Frizzled receptors and Wnt/β-catenin signaling</strong></a></h4><p>Miroslav Micka, Jitender Kumar, Petra Paclíková, Zuzana Hayek, Kateřina Hanáková, Cherine Bechara, Hana Plešingerová, Ondrej Šedo, Sara Bologna, Elise Del Nero, Kristína Gömöryová, Vojtěch Bystrý, Tomáš Gybel, Tereza Čihalová, Marek Kravec, David Potěšil, Zbyněk Zdráhal, Konstantinos Tripsianes a Vítězslav Bryja.</p><p><i><strong>Sci. Adv., 2026, 12(20), eaed8899</strong></i></p><p><a target="_blank" rel="noopener noreferrer" href="https://doi.org/10.1126/sciadv.aed8899">DOI: 10.1126/sciadv.aed8899</a></p><h6>licenced under <a target="_blank" rel="noopener noreferrer" href="https://creativecommons.org/licenses/by/4.0/"><strong>CC-BY 4.0</strong></a></h6></blockquote><h4><strong>Abstract</strong></h4><p>It is well known that Dishevelled (DVL) phosphorylation by casein kinase 1 (CK1) relays Wnt signals from Frizzled (FZD) receptors to downstream effectors, yet any mechanistic aspects of DVL function related to phosphorylation remain unresolved. Here, we uncovered a Wnt-induced DVL phospho-switch that is mutually exclusive with FZD association. CK1 multiphosphorylation changes dramatically the bulk electrostatics to promote DVL intramolecular interaction between the DEP domain and the adjacent disordered region. A panel of DVL3 mutants demonstrated a switch-like behavior at the molecular level when a charge threshold was reached. Charge accumulation proximal to DEP proved to be a key functional event required, but not sufficient, for Wnt/β-catenin signaling. Proximity interactomics revealed FZD receptors as the prominent effectors of the DVL phospho-switch function consistent with the molecular competition at the DEP interface. By integrating findings at different levels, we propose a universal mechanism, in which Wnt-induced DVL conformational phospho-switch attenuates coresidence with FZDs as a means for downstream signaling events.</p>

 Scientists Uncover a Tipping Point in Cells. This Is How Cancer May Begin 

<div><div><p><strong>Deoxyribozymes represent a new frontier in biotechnology. They show that DNA is much more than a storage molecule for genetic information: it can also function as a catalytic machine. Unlike traditional enzymes made of proteins, such DNA-based tools are stable, easy to produce in large quantities, and can be evolved in a lab to perform different chemical tasks we need. Their potential is vast, ranging from low-cost diagnostic kits to high-speed screening tools that can facilitate drug discovery. As our ability to understand and predict their behavior continues to improve, these versatile molecules are becoming a cornerstone for future personalized medicine and environmental monitoring.</strong></p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/IOCB_Prague_Deoxyribozymes_tools_for_precision_sensing_and_machine_learning_guided_discoveries_e771c8c360.jpeg" alt="IOCB Prague: Deoxyribozymes, tools for precision sensing and machine learning-guided discoveries: Researchers described a new assay for DNA-editing enzymes in which the substrate in the reaction is a chemiluminescent deoxyribozyme called Supernova. ACS Chem. Biol. 2026, 21, 5, 941-950" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_IOCB_Prague_Deoxyribozymes_tools_for_precision_sensing_and_machine_learning_guided_discoveries_e771c8c360.jpeg 245w," sizes="100vw" width="1049" height="561"></p></div></div><div><p>Researchers led by <a target="_blank" rel="noopener noreferrer" href="https://curtis.group.uochb.cz/en"><strong>Edward Curtis</strong></a> from IOCB Prague have developed a remarkable DNA molecule called Supernova that acts as a tiny biological flashlight, glowing blue during a specific chemical reaction. By tweaking its sequence, scientists transformed Supernova into a sensor capable of detecting DNA-editing enzymes, which are proteins that alter the sequence of DNA and are often linked to the development of cancer. These new sensors represent a step forward because they are roughly three times faster and over five times cheaper than standard assays. Depending on how they are designed, these sensors can be either "turned off" or "turned on" by a DNA-editing enzyme in a sample. Such sensors will make characterization of DNA-editing enzymes easier, and could also help scientists to find new inhibitors.</p><div><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/IOCB_Prague_Deoxyribozymes_tools_for_precision_sensing_and_machine_learning_guided_discoveries_2_8e228a1903.jpeg" alt="IOCB Prague: Deoxyribozymes, tools for precision sensing and machine learning-guided discoveries: Researchers also systematically investigated the specificities of self-phosphorylating deoxyribozymes that convert the coumarin substrate 4-MUP into a fluorescent product using biochemical assays, single-step selections, and machine learning. ACS Chem. Biol. 2026, 21, 5, 951-959" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_IOCB_Prague_Deoxyribozymes_tools_for_precision_sensing_and_machine_learning_guided_discoveries_2_8e228a1903.jpeg 245w," sizes="100vw" width="1561" height="505"></p><p>In another advance, researchers in the Curtis Group used a fluorescent deoxyribozyme named Aurora to explore how these molecular tools can be taught to recognize specific chemical targets. Using a combination of artificial evolution and machine learning, the team successfully identified specific mutations that change Aurora’s preference for one substrate over another. Machine learning is particularly powerful here because it allows researchers to predict how millions of different DNA variants will behave without having to test each one individually in a lab. This approach helps us understand the fundamental rules of how DNA molecules interact with the world, which is essential for designing more precise medicines and diagnostic tools.</p><h3><strong>These results are described in two recent publications:</strong></h3><blockquote><h4><a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acschembio.5c00927"><strong>Chemiluminescent Deoxyribozyme Sensors for DNA-Editing Enzymes</strong></a></h4><p>Jakubec, M.; Svoboda, M.; Kurfürst, J.; Svehlova, K.; Veverka, V.; Curtis, E. A. &nbsp;</p><p><i>ACS Chem. Biol. </i><strong>2026</strong></p><p><a target="_blank" rel="noopener noreferrer" href="http://doi.org/10.1021/acschembio.5c00927">http://doi.org/10.1021/acschembio.5c00927</a></p><h6><strong>licensed under </strong><a target="_blank" rel="noopener noreferrer" href="https://creativecommons.org/licenses/by/4.0/"><strong>CC-BY 4.0</strong></a></h6></blockquote><h4><strong>Abstract</strong></h4><p>DNA-editing enzymes such as those in the APOBEC family of cytidine deaminases play important roles in both normal and pathogenic function, while engineered enzymes offer exciting new possibilities for genome editing. Despite their importance, widely used assays for DNA-editing enzymes are time-consuming and expensive. Here, we describe a new assay for DNA-editing enzymes in which the substrate in the reaction is a chemiluminescent deoxyribozyme called Supernova. Editing alters the sequence of Supernova, which results in a change in catalytic activity and light production. By analyzing a data set of Supernova variants previously identified by selection and high-throughput sequencing, it was possible to generate sensors with a wide range of specificities. Sensors were also developed for APOBEC3A, a cytidine deaminase which converts C to U in single-stranded DNA and RNA. These include a turn-off sensor that produces light 14-fold slower after incubation with recombinant APOBEC3A than in its absence, and a turn-on sensor that generates light 10-fold faster after incubation with APOBEC3A than in its absence. Assays that use these sensors are faster and less expensive than existing ones, and should be particularly useful for applications such as high-throughput screening.</p><blockquote><h4><a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acschembio.5c00969"><strong>Probing the Specificity of Fluorescent Deoxyribozymes Using Single-Step Selections and Machine Learning</strong></a></h4><p>Král’ová, Z.; Isler, L.; Volek, M.; Jandová, M.; Kurfürst, J.; Curtis, E. A.&nbsp;</p><p><i>ACS Chem. Biol. </i><strong>2026</strong>&nbsp;</p><p><a target="_blank" rel="noopener noreferrer" href="http://doi.org/10.1021/acschembio.5c00969">http://doi.org/10.1021/acschembio.5c00969</a></p><h6><strong>licensed under </strong><a target="_blank" rel="noopener noreferrer" href="https://creativecommons.org/licenses/by/4.0/"><strong>CC-BY 4.0</strong></a></h6></blockquote><h4><strong>Abstract</strong></h4><p>The ability of proteins and nucleic acids to form specific binding sites for ligands is critical for biological function, and methods to modulate biochemical specificity are important for fields such as enzyme engineering and drug design. Here, we systematically investigated the specificities of self-phosphorylating deoxyribozymes that convert the coumarin substrate 4-MUP into a fluorescent product using biochemical assays, single-step selections, and machine learning. Activity assays using a panel of 20 catalytic motifs and 10 substrates that generate different types of signals when they are dephosphorylated revealed that these deoxyribozymes are extremely specific for 4-MUP. To identify mutations that change specificity, we constructed a library based on a self-phosphorylating fluorescent deoxyribozyme called Aurora. A series of single-step selections yielded variants that react with 4-MUP and the structurally similar substrate diFMUP, but not with the more distinct substrates pNPP and ELF. Pairwise analysis of sequences in the 4-MUP and diFMUP data sets revealed four mutations that modulate Aurora specificity. The effects of these mutations were confirmed using biochemical assays and could be predicted using models developed by machine learning. Taken together, our results show how single-step selections can be used to identify mutations that change the specificity of a deoxyribozyme. They also highlight how machine learning can be used to model complex data sets from <i>in vitro</i> selection experiments.</p></div></div>

Deoxyribozymes, tools for precision sensing and machine learning-guided discoveries

Article

Webinars

Video

Water

Science and research

For more than 40 years, ALS has provided testing and technical solutions to clients all over the world in a wide range of industries. We have built our global reputation by embracing the latest technologies and innovative methodologies to deliver high quality testing services to clients. ALS is able to leverage a multifaceted international team while remaining agile enough to provide local expertise and personalized solutions to every one of our clients.

ALS Czech Republic

Since its establishment in 2011, CEITEC has quickly developed into a cutting-edge infrastructure for research which performs highly alongside the best institutes in Europe. Among the main priorities of CEITEC are the promotion of a motivating and dynamic international scientific environment, the provision of state-of-the-art research infrastructure, and the policy of open communication and equal opportunities.

CEITEC

The Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB Prague) is a leading scientific institution in the Czech Republic, recognized internationally. Its primary mission is basic research in the fields of chemical biology and medicinal chemistry, organic and material oriented chemistry, chemistry of natural compounds, biochemistry and molecular biology, physical chemistry, theoretical chemistry, and analytical chemistry. 

Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences

Agilent Technologies

Bruker

Thermo Fisher Scientific

SelectScience

SCIEX

Waters Corporation

<h3><strong>A five-part webinar series unlocking advanced insights across the Peptide therapeutics workflows</strong></h3><p><strong>Peptide therapeutics are reshaping modern medicine, with GLP-1 receptor agonists driving rapid advances in metabolic disease treatment. As peptide and GLP-1 programs scale, scientists face increasing pressure to generate data that is accurate, defensible, and decision-ready across development stages.</strong></p><p>Peptide 360 is designed to guide scientists through this complexity, following the peptide workflow from sequence insight to confident development decisions.</p><h5><strong>Who Should Attend?</strong></h5><p>This series is designed for scientists and technical leaders working in peptide and GLP-1 discovery and development, analytical development, characterization, Bioanalysis, DMPK, translational research, CMC, QA/QC, and regulatory-facing analytical roles</p><h5><strong>How the Series Works?</strong></h5><ul><li>Register once for the full series</li><li>Pre-submit questions for live expert responses</li><li>Access recordings anytime after each session</li><li>Certificate of attendance provided</li></ul><h4><strong>Episode 5: Resolving GLP-1 Impurities Using Orthogonal RPLC and HILIC Approaches</strong></h4><p>GLP-1 receptor agonists exhibit structural complexity and susceptibility to degradation, making robust impurity separation essential for quality control and regulatory compliance. This session highlights the use of orthogonal chromatographic approaches, reversed-phase liquid chromatography (RPLC) and hydrophilic interaction chromatography (HILIC), to improve impurity resolution and detection.</p><p>Attendees will learn practical method development strategies, including gradient design, column selection, temperature control, and mobile phase optimization. The session demonstrates how combining orthogonal separations enhances confidence in impurity profiling and supports reliable characterization of GLP-1 analogs in development and QC environments.</p><blockquote><p><strong>Presenter: </strong>Andrea Ngai (Biopharma Technical Specialist, Agilent Technologies, Inc.)</p><p><strong>Presenter:&nbsp;</strong>Ashish Pargaonkar, Ph.D. (Biopharma Applications Specialist, Agilent Technologies, Inc.)</p></blockquote>

Agilent Technologies: Peptide 360: Mastering the Invisible from Sequence to Confidence

Resolving GLP-1 Impurities Using Orthogonal RPLC and HILIC Approaches

Peptide 360 Episode 5 webinar on orthogonal RPLC and HILIC methods for GLP-1 impurity separation and QC-ready characterization.

Resolving GLP-1 Impurities by Orthogonal RPLC and HILIC

<h3><strong>Pharma and biopharma fundamentals masterclasses</strong></h3><h5><strong>Build confidence in your analytical decisions across pharma and biopharma workflows</strong></h5><p>The pharma and biopharma fundamentals masterclasses are a year-long educational series designed for scientists who want to strengthen their knowledge, compare analytical strategies, and apply best practices across regulated workflows.</p><p>Each session focuses on a real analytical challenge — from quantitation and metabolite identification to biopharma characterization and extractables and leachables — with practical guidance from SCIEX experts.</p><p>Attend live or watch on demand and choose the sessions most relevant to your work.</p><h4><strong>Available now:</strong></h4><h5><strong>Pharma fundamentals: Metabolite Identification Metabolite identification is essential in drug discovery, supporting confident decisions in compound design and toxicology</strong></h5><p>This session shows how alternative fragmentation strategies can overcome limitations of traditional CID and improve MetID accuracy for complex metabolites.</p><ul><li><strong>Speaker: </strong>Heather Chassaing, Senior Accurate Mass Workflow Specialist, SCIEX</li></ul><h4><strong>Upcoming sessions</strong></h4><h5><strong>3. Pharma fundamentals: To Be or Not to Be? QQQ vs HRMS Quant</strong></h5><p>Discover how QQQ and HRMS stack up for quantitation in bioanalysis, from sensitivity to workflow efficiency. Learn best practices using SCIEX 7500+ and ZenoTOF 7600 systems to make confident, data-driven decisions.&nbsp;</p><blockquote><p><strong>Speaker:</strong> Cathy Lane, Sr. Application Lead, SCIEX</p><p>Cathy joined SCIEX in 2006 as a Support Specialist and in 2021 took up the role of EMEAI Applications Lead for Pharma &amp; Peptide Quant. She has 25 years’ experience in the development of LC-MS methods for the analysis of small and large molecules. She has a PhD in mass spectrometry-based proteomics from the University of London School of Pharmacy, an MSc in Forensic Science from King’s College London and an MA in Chemistry from the University of Oxford.</p></blockquote>

SCIEX: Pharma and biopharma fundamentals masterclasses

Pharma fundamentals: To Be or Not to Be? QQQ vs HRMS Quant

Pharma masterclass comparing QQQ vs HRMS quantitation with SCIEX 7500+ and ZenoTOF 7600 for confident bioanalysis decisions.

Biopharma fundamentals: LCMS Biopharma characterization

<h3><strong>Bringing laboratory automation to life with Andrew+ and OneLab</strong></h3><p>This webinar series explores how Andrew+ automated liquid handling and OneLab workflow software support consistent, traceable and efficient laboratory operations. Through application‑focused episodes, you will see how automation can be successfully integrated into everyday laboratory workflows, from method development to routine and regulated environments, supported by real‑world customer experiences and testimonials.</p><h4><strong>Episode 4 – Food &amp; Environmental Workflows</strong></h4><h4><span style="color:#212121;"><strong>Overview</strong></span></h4><p>Food and environmental testing laboratories face complex matrices, high sample volumes and strict quality requirements. This episode highlights how automation helps standardise sample preparation while reducing manual workload and operational risk, with <strong>direct insight from laboratories applying these solutions in routine testing.</strong></p><h4><span style="color:#212121;"><strong>Key highlights</strong></span></h4><ul><li>Standardise sample preparation in complex food and environmental matrices</li><li>Improve repeatability by automating pipetting and solid phase extraction (SPE) workflows</li><li>Support auditing, troubleshooting and regulatory needs through automated workflow documentation</li></ul><blockquote><p><strong>Speaker: Xavier Rodriguez </strong>(Principal Applications Specialist, Chemistry, Europe - Waters Corporation)</p><p>Xavier is part of the European Market Development Team. He works as an Application Specialist with focus on sample prep and has more than 20 years of experience in solving sample prep challenges.</p><p><strong>Customer testimonials: Labexia </strong>– Groupe CARSO</p><p>Labexia is part of Groupe CARSO, a European analytical services group specialising in food testing, environmental analysis and routine laboratory services.</p><p>In this episode, Labexia shares how automation has been implemented in day‑to‑day food testing workflows to streamline pipetting and sample preparation activities. The testimonial illustrates how automated liquid handling helps free up technicians’ time, improve repeatability and reduce the risk of musculoskeletal strain in routine laboratory operations.</p></blockquote><h5><strong>Reserve Your Spot Today!</strong></h5>

Transform Your Daily Lab Operations with Automation - Food and Enviromental Workflows

Automate food and environmental testing workflows. Learn how Andrew+ and OneLab standardize sample prep, automate SPE, and improve laboratory traceability

Automated Food & Environmental Lab Workflows

<h4><strong>How Transformative New Software Solutions Are Elevating Quality and Compliance</strong></h4><p>As organizations navigate the challenges of increasing efficiency and productivity without compromising quality or compliance, new software solutions are emerging that enable labs to reduce risk with vigilant monitoring, ensure precision, and uphold the highest standards of compliance. By streamlining processes, reducing error and downtime, and providing real-time insights, these innovations not only improve operational efficiency but also help laboratories meet stringent regulatory requirements for quality management maturity. Join us to uncover how embracing these innovations can make our lives better and safer by fostering a culture of accountability, quality improvement, and sustainable compliance.</p><h5><br><strong>Agenda includes</strong></h5><ul><li><strong>Introduction</strong></li><li><strong>Regulation Meets Innovation | Waters Data Strategy in the Cloud</strong><ul><li>Mario Rossi- Informatics Market Development Director</li></ul></li><li><strong>Innovative Software Tool Demonstration</strong><ul><li>Jason Loftus- Pr. Informatics Business Development Specialist</li></ul></li></ul><blockquote><p><strong>Speaker: </strong>Jason Loftus (Senior Informatics Sales Development Specialist, Waters Corporation)</p><p>After getting his BS in Chemistry, Jason worked as a QC Chemist for a consumer products company in Massachusetts. In 1998, he joined Waters as a Field Service Engineer based in Boston, MA. In 2001, he left Waters to join a biopharma company in Colorado, but returned to Waters in 2004 as a Field Service Engineer covering the southwestern US. In 2010, he became the Service Manager for the Mountain Region covering most of the western US. In 2016, he joined the Informatics Sales Development team and currently covers the western US, western Canada, and the southeastern US.</p><p><strong>Moderator:</strong> Mario S. Rossi, PE (Enterprise Informatics Market Development Director, Waters Corporation)</p><p>Mario has over 20 years of experience in the pharmaceutical life sciences industry, with deep expertise in laboratory informatics. In his current role, he leads strategic initiatives to expand and accelerate the adoption of Waters enterprise informatics solutions, including Empower Enterprise, NuGenesis LMS, waters_connect network, and Waters’ cloud-based applications. Since joining Waters in 2004, Mario has held a variety of leadership roles across technical presales, business development, and informatics sales. Prior to Waters, he served as an engineer at New Brunswick Scientific and Wallace &amp; Tiernan. Mario holds an MBA in Marketing and a BS in Electrical Engineering from the University of South Florida. He is also a licensed Professional Engineer in the State of New Jersey.</p></blockquote>

How Transformative New Software Solutions Are Elevating Quality and Compliance

Explore new laboratory software solutions and cloud data strategies. Reduce risk, ensure precision, and meet strict regulatory compliance requirements

New Software Solutions for Quality & Compliance

<p><strong>Mass spectrometry (MS) now produces richer, more complex datasets than ever, offering biopharmaceutical teams new opportunities to deepen biological insight and accelerate discovery. Unlocking this potential requires transforming raw MS outputs into structured, automated, and analysis‑ready data that can support scalable workflows, reproducible analytics, and AI‑driven prediction models.</strong></p><p>In this SelectScience® webinar, learn from Dr. Joomi Ahn, Senior Director at Eli Lilly, as she shares how the Biologic Discovery Mass Spectrometry group implemented Genedata Expressionist to build an integrated digital ecosystem. By connecting electronic lab notebooks, liquid‑handling automation, and custom artificial intelligence and machine‑learning tools, the team achieved 3–10× productivity gains.</p><p>By registering for this webinar, you will hear first‑hand how these capabilities now enable high‑throughput intact mass analysis, bispecific assembly checks, and stability peptide mapping. This flexible, vendor‑neutral foundation can help teams accelerate their workflows and unlock insights that drive the next wave of biologic drug discovery.</p><h4><strong>What will this webinar cover?</strong></h4><ul><li>How to standardize MS workflows across sites with a scalable, vendor-neutral, flexible platform</li><li>How to automate end-to-end MS processes to increase productivity, data integrity, and knowledge access</li><li>How to integrate wet and digital labs to shorten developability timelines for any new and hybrid modality</li><li>How to leverage sequence liability prediction and automated stability reporting to accelerate drug candidate selection</li></ul><h4><strong>Who should attend?</strong></h4><ul><li>Analytical scientists and innovation leaders looking for scalable, vendor-neutral ways to standardize and automate MS workflows across labs and sites.</li><li>Developability and CMC characterization stakeholders using MS data and digital platforms to streamline biologics discovery and development, reduce optimization cycles, and accelerate timelines.</li><li>VP/Director-level biopharma leaders building digital foundations in R&amp;D and evaluating how AI and digital tools can accelerate timelines and deliver measurable impact.</li><li>IT, informatics, and scientific software developers integrating legacy systems, enabling scalable infrastructure, and delivering user-friendly tools that strengthen scientific workflows.</li></ul><h4><strong>Certificate of attendance</strong></h4><p>If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes. If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.</p><h4><strong>Webinar details</strong></h4><ul><li>Cost: Free to attend</li><li>Location: Online</li><li>Duration: 60 minutes</li></ul><p><i>Registration is required to secure your place. If you register but can’t attend live, you will receive a link to the on‑demand recording once it becomes available.</i></p><blockquote><p><strong>Speaker:</strong> Dr. Joomi Ahn (Senior Director, Mass Spec Analytical BioTDR, Eli Lilly)</p><p>Dr. Joomi Ahn is a Senior Director at Eli Lilly and Company, where she leads the Mass Spectrometry Analytical Group within Biologics Discovery at the San Diego site. With more than 25 years of biopharmaceutical industry experience at AstraZeneca, AbbVie, and Waters Corporation, she has contributed to multiple protein therapeutic pipelines across early- to late-stage analytical and process development. Dr. Ahn holds a Ph.D. in Chemistry and Chemical Biology from Northeastern University, has authored 13 peer-reviewed publications, and is a co-inventor on a granted patent.&nbsp;</p><p><strong>Moderator:</strong> Ada Yee (Scientific Communications &amp; Engagement, Corporate, Genedata)</p><p>Ada Yee is a scientific communications professional dedicated to helping scientists and leaders communicate complex ideas clearly and effectively. With an academic background at Berkeley and Stanford, she brings a strong foundation in research communication and a passion for impactful scientific storytelling.</p><p><strong>Moderator:</strong> Olivia Long (Editorial Team, SelectScience)</p><p>Olivia Long is a science editor specializing in pharmaceutical and applied science. She has a BSc in Pharmacology, and an MSc in Neuroscience, where she investigated neuro‑oncology drug‑resistance pathways using patient‑derived cell models. Her laboratory experience spans R&amp;D hygiene testing, controlled‑environment sample production, and protocol development, giving her a broad understanding of analytical workflows and the scientific principles underpinning biopharmaceutical quality control.</p></blockquote>

SelectScience: Mass spec data digital transformation at Lilly Biologics Discovery

Mass spec data digital transformation at Lilly Biologics Discovery

Webinar on mass spectrometry digital transformation. Learn how to automate MS workflows, leverage AI, and accelerate biologic drug discovery timelines.

Mass spec data digital transformation

<div><h4><strong>Overview</strong></h4><p>Most of what happens inside a tissue, a tumor, or a 3D cell model is chemically invisible to conventional analysis. The molecular organization is there. The spatial relationships are there. MALDI Imaging is now the tool that makes them visible, from individual cells to complex tissue architectures. This webinar explores what that visibility looks like at the frontier.</p><p>In this webinar, <strong>Prof. Hopf (CeMOS, TH Mannheim)</strong> will present his group's latest findings across the full range of MALDI Imaging-based spatial analysis, from established tissue workflows to single-cell imaging and complex biological systems.</p><p>Starting with well‑established tissue workflows, the talk will demonstrate how spatial molecular analysis can uncover altered metabolic and proteomic phenotypes linked to differentiation, disease, or chemical exposure. A particular focus will be placed on toxicology‑relevant applications, showing how label‑free MALDI Imaging enables the unambiguous molecular identification of protein accumulations in kidney tissue, supporting reliable decision‑making in preclinical safety assessment where conventional histology and immunohistochemistry reach their limits.</p><p>The webinar will then focus on two rapidly developing fields: single‑cell molecular imaging for dissecting cellular activation states, and 3D biology. 3D data. 3D visualization. All in one workflow. Hopf's group applies MALDI Imaging to 3D cell culture disease models including organoids and spheroids, generating volumetric spatial molecular data that can be explored end-to-end in mixed reality, from sample to insight, the geometry is preserved throughout.</p><p>Finally, advanced data reconstruction and visualization strategies will be presented that enable researchers not only to analyze but to interactively explore spatial molecular landscapes in mixed reality, opening new perspectives for spatial biology, toxicological research, and translational and pharmaceutical applications.</p><h4><strong>Key Learning Objectives</strong></h4><ul><li>See how MALDI Imaging extends spatial molecular analysis beyond conventional tissue sections into single cells and complex biological systems</li><li>Learn how molecular imaging supports toxicological decision‑making through label‑free, in situ protein identification</li><li>Experience how mixed reality visualization transforms the way researchers interact with complex spatial molecular datasets</li><li>Gain insight into advanced workflows and visualization strategies for complex spatial datasets</li><li>Discover how MALDI Imaging contributes to biological, pharmaceutical, and safety‑related research</li></ul><h4><strong>Who Should Attend</strong></h4><ul><li>Researchers in spatial biology and imaging mass spectrometry</li><li>Scientists working in metabolomics, lipidomics, proteomics, and tissue analysis</li><li>Toxicologists and pharmaceutical researchers involved in preclinical safety assessment</li><li>Researchers interested in single-cell and 3D spatial omics approaches</li><li>Drug discovery scientists using 3D tissue models or organoids for target identification or compound profiling</li><li>Analytical and translational scientists working on biologics, ADCs, or LNP spatial distribution characterization</li></ul><blockquote><p><strong>Presenter:</strong> Carsten Hopf, Ph.D. (Professor and Head, Center for Mass Spectrometry and Optical Spectroscopy (CeMOS), Technische Hochschule Mannheim, Germany)</p><p>Prof. Hopf's group at CeMOS has contributed foundational methods in MALDI-based spatial proteomics, metabolomics, and tissue model imaging, with applications ranging from neuroscience to toxicological safety assessment. His group's 3D MALDI Imaging platform was recently published in Advanced Science (2026).<br>&nbsp;</p></blockquote></div>

Bruker: MALDI Imaging at the Frontier - Single-Cell Analysis

MALDI Imaging at the Frontier: Spatial Metabolomics, Single-Cell Analysis, and 3D Exploration in Mixed Reality

Advance drug discovery with MALDI Imaging. Explore how spatial metabolomics, single-cell analysis, and 3D mixed reality accelerate preclinical research.

MALDI Imaging Frontier: 3D Spatial Biology Trends

<p><strong>Discover how combustion ion chromatography and high-resolution mass spectrometry work together to streamline PFAS screening, improve confidence, and future-proof your lab.</strong></p><h4><strong>Summary</strong></h4><p>Per- and polyfluoroalkyl substances (PFAS) continue to challenge laboratories with evolving regulations, complex matrices, and the need for both targeted and non-targeted analysis.</p><p>In this webinar, we explore how combining Thermo Scientific™ Cindion™ Combustion Ion Chromatography (C-IC) with Thermo Scientific™ EFOX analytical solutions enables a more efficient, scalable approach to PFAS screening, helping laboratories identify unknowns, prioritize samples, and meet compliance demands faster.</p><p>Combustion IC provides a powerful screening tool by measuring total adsorbable organic fluorine (AOF)—an indicator of PFAS presence beyond targeted lists—while high-resolution mass spectrometry workflows enable confident identification and quantitation of known and emerging compounds.</p><h5><strong>Why Attend?</strong></h5><ul><li>Screen beyond targeted PFAS lists - Detect total organofluorine (AOF/TOF) to uncover hidden or unknown PFAS in complex samples.</li><li>Improve sensitivity and reduce contamination risk - Learn how the Cindion system minimizes PFAS background and enables highly sensitive detection aligned with EPA Method 1621 workflows.</li><li>Optimize lab efficiency and throughput - Use screening data to prioritize samples for confirmatory LC-MS/MS or HRMS analysis, reducing unnecessary runs.</li><li>Future-proof your PFAS analysis - Leverage EFOX full-scan, high-resolution data for retrospective analysis of newly regulated compounds, without reinjecting samples.</li><li>Streamline workflows from sample to result - Integrate automated workflows, simplified software, and ready-to-use methods to reduce method development and training time.</li></ul><h5><strong>What You’ll Learn</strong></h5><ul><li>The role of combustion ion chromatography (C-IC) in PFAS screening</li><li>How AOF/TOF measurements complement targeted LC-MS/MS methods</li><li>Best practices for implementing EPA Method 1621 workflows</li><li>How EFOX high-resolution MS enables both targeted quantitation and non-targeted discovery</li><li>Strategies to combine screening + confirmation workflows for maximum efficiency</li><li>Real-world applications across water, food packaging, environmental, and industrial samples</li></ul><blockquote><p><strong>Speaker: </strong>Todd Stoner (Sr Product Specialist, Thermo Fisher Scientific)</p><p>Todd Stoner is a senior technical sales leader with 30+ years in analytical sciences. At Thermo Fisher Scientific, he supports environmental and food safety markets across Eastern North America, specializing in chromatography and mass spectrometry. He drives sales strategy, mentors teams, and is known for collaboration and customer-focused solutions.</p></blockquote><blockquote><p><strong>Presenter:</strong> Alain Carriere (Sr Product Specialist, Thermo Fisher Scientific)</p><p>Alain D. Carriere is a Senior Technical Sales Specialist at Thermo Fisher Scientific with 30+ years in scientific instrumentation, specializing in ion and liquid chromatography. He has supported environmental, pharma, and academic labs, and previously worked at the University of Guelph. He holds an Honours BSc and has published in analytical biochemistry.</p></blockquote>

Thermo Scientific: Smarter PFAS Screening with Combustion IC + HRMS

Find What You’re Missing: Smarter PFAS Screening with Combustion IC + HRMS

Advance PFAS screening using Combustion IC + HRMS. Measure total organic fluorine (AOF/TOF) and leverage high-resolution MS for confident non-targeted discovery

Smarter PFAS Screening with Combustion IC + HRMS

<p><strong>We are pleased to invite you to our upcoming free online webinar focused on one of the most pressing challenges in environmental monitoring and water quality management — PFAS (Per- and Polyfluoroalkyl Substances).</strong></p><p>As regulatory frameworks continue to evolve and compliance deadlines approach, laboratories, water utilities, and environmental professionals need robust, reliable, and cutting-edge analytical solutions to stay ahead.</p><h4><strong>🎤 Our Speaker</strong></h4><p>The webinar will be hosted by <strong>Jana Kováčová, Ph.D., PFAS Regional Lead for Continental Europe Environmental Division</strong>, who has dedicated the last several years to the field of PFAS analysis and determination in ALS laboratories. Jana is a recognized expert in PFAS environmental analytics and will share practical insights and the latest developments in analytical strategies to help your organization achieve and maintain compliance.</p><h4><strong>🎯 What You Will Learn</strong></h4><ul><li>Latest <strong>regulatory developments</strong> and compliance requirements for PFAS in water, including <strong>EU Drinking Water Directive 2020/2184</strong> and its implications for water suppliers and laboratories.</li><li><strong>Regulatory updates for surface water and groundwater</strong> — what's new and what to expect next.</li><li>Overview of <strong>advanced analytical strategies</strong> for PFAS detection and quantification in water matrices and how we analyse PFAS samples.</li><li>Key <strong>analytical challenges</strong> associated with PFAS testing — from ultra-trace detection to matrix interferences and contamination control.</li><li>The critical importance of using tested <strong>sampling containers</strong> and sample preservation to ensure reliable results.</li><li>Illustrative <strong>examples of results</strong> from real-world PFAS water analyses.</li><li>How ALS can support your needs with <strong>accredited PFAS testing services</strong>.</li></ul><h4><strong>👥 Who Should Attend</strong></h4><p>This webinar is designed for our clients, professionals, laboratory and technical staff, scientists, as well as anyone with an interest in analytical chemistry who wants to better understand the occurrence of these "forever chemicals" in the environment. &nbsp;</p><h4><strong>💬 Q&amp;A Session</strong></h4><p>There will be a live Q&amp;A session at the end of the webinar. You are welcome to submit your questions in advance during registration or ask them live on the day.</p><h4><strong>📅 Additional Webinar Info:</strong></h4><ul><li><strong>Platform: </strong>Microsoft Teams (online)</li><li><strong>Language: </strong>English</li><li><strong>Duration:</strong> approx. 45 - 60 minutes (incl. Q&amp;A)<br>Extras: If you are unable to attend on the day, please register and we will provide you with the recording of the webinar.</li></ul><h4><strong>🔬 About ALS Environmental</strong></h4><p>ALS is a global leader in environmental testing and analytical services, providing accredited PFAS analysis to clients across Europe and beyond. Our dedicated PFAS experts help clients navigate the complex regulatory landscape with confidence.</p><p>For further information, please contact us on: <strong>marketing.cz@alsglobal.com</strong></p><p>We look forward to welcoming you to this important discussion on PFAS compliance in water.</p><blockquote><p><strong>Speaker</strong> Jana Kováčová (PFAS Regional Lead - Continental Europe)</p><p>Jana Kováčová is an analytical chemist with over 15 years of experience in method development and validation. She earned her MSc and PhD from the University of Chemistry and Technology, Prague (UCT Prague), where she specialized in analytical methods for pesticide residue determination in water and food matrices of both plant and animal origin. In 2020, Jana joined ALS Czech Republic as a Validation Specialist within the environmental analytical innovations group, later transitioning to a full-time focus on PFAS (per- and polyfluoroalkyl substances) analytics. In 2022, she was appointed Supervisor of the PFAS Section. Currently, Jana serves as the PFAS Lead for Continental Europe. In this role, she coordinates ALS’s PFAS analytical activities across the region, acting as a key technical representative for PFAS topics. She supports laboratories and clients with strategic guidance and data interpretation, aligns testing approaches across multiple sites, and ensures consistent, high-quality delivery. To stay at the forefront of the field, Jana closely monitors legislative updates and emerging trends, sharing her expertise through client webinars, seminars, and presentations at scientific conferences.</p></blockquote>

ALS: PFAS in Water 2026: Achieving Compliance through Advanced Analytical Strategies

PFAS in Water 2026: Achieving Compliance through Advanced Analytical Strategies

Join ALS experts to explore PFAS regulations, water testing challenges, analytical methods, and compliance strategies for environmental monitoring.

PFAS in Water - Analytical strategies

<h4><strong>Get Tips on Current Dissolution Challenges Meet with industry experts: Join the Dissolution Discussion Group webinars.</strong></h4><p><strong>Dissolution testing involves a series of unit operations, each of which can be automated. But which step is the right one to automate your lab?</strong></p><p>Join us for this webinar as we explore the latest regulations on automation and provide expert guidance on implementing new automation steps tailored to your laboratory's needs. Whether you're a seasoned professional or just starting out, this session is designed to help you navigate the path to increased automation, ensuring your lab operates at its best.</p><p>This session will take a unique approach by opening the floor to any questions related to dissolution testing, rather than focusing on a single topic. Attendees are encouraged to engage with the panel of experts on a wide range of subjects—from navigating method development and understanding where to begin, to tackling specific formulation challenges or seeking guidance on regulatory matters. Our goal is to address as many of your questions as possible, fostering an interactive environment that supports learning and practical problem solving.</p><p>.</p><blockquote><p><strong>Presenter:</strong> Karen Krauel-Göllner, PhD (Product Manager Dissolution, Agilent Technologies, Inc.)</p><p>Karen Krauel-Göllner is a registered pharmacist and holds a PhD in Pharmacy from the University of Otago, New Zealand. Karen has worked in various roles in the field of pharmaceutical development. For the last 10 years she has been working at Agilent Technologies and currently holds a position as product manager for dissolution systems.</p><p><strong>Presenter:</strong> Ken Boda (Dissolution Product Specialist, Agilent Technologies, Inc.)</p><p>Ken joined Varian (now Agilent) in 2005 as an applications engineer and is now a dissolution product specialist. Prior to working at Agilent, he worked in pharma specializing in dissolution testing and method development. As a dissolution product specialist, Ken works with customers in determining the best systems for their needs and optimizing their workflows. He has also helped educate customers on dissolution science through webinars, the Dissolution Discussion Group, LinkedIn, and other channels.</p><p><strong>Presenter: </strong>Bryan Crist (President, DissoAssist Consulting, Wilmington, NC, USA)</p><p>Bryan has been the president of DissoAssist Consulting based in Wilmington, NC, USA since 2021. He provides consulting, coaching, and training services for dissolution and drug release in the pharmaceutical industry. Bryan is also an active member on various USP Expert Committees. Previously, Bryan was a scientific affairs manager with Agilent Technologies located in Cary, North Carolina, USA. From 1997 to 2021, he focused on providing method and technical application support for dissolution and drug release testing in the pharmaceutical industry as well as working with VanKel, Varian, and eventually Agilent. Prior to 1997, Bryan supervised and managed pharmaceutical laboratories and performed analytical testing with Bristol-Myers Squibb, Merck, AAI, and Abbott Laboratories until he joined the dissolution equipment manufacturer VanKel.</p><p><strong>Presenter: </strong>Vivian Gray (Founder VA Gray Consulting; Managing Director of Dissolution Technologies)</p><p>Vivian has spent the last 40+ years involved in all aspects of dissolution testing and evaluating new dissolution technology. At the United States Pharmacopeia, she enjoyed a long career serving first as a bench chemist, supervisor, and lastly as a liaison to various expert USP committees. In 1997, Vivian joined the DuPont-Merck Pharmaceuticals Company Analytical Research and Development Section as the head of the Dissolution Group. In 2002, she formed her own consulting business, V. A. Gray Consulting, Inc., in dissolution testing and related areas. In June 2003, she became managing director of Dissolution Technologies, a peer-reviewed journal dealing specifically with dissolution testing issues.</p><p><strong>Presenter:&nbsp;</strong>Pearl Pereira (Founder, RegXpertPRO)</p><p>Pearl Pereira - Nambiar is the Founder of RegXpertPRO and a pharmaceutical analytical development and regulatory CMC professional with 23 years of experience. She specializes in dissolution strategy, specifications, analytical methods, dissolution profile comparison and regulatory deficiency responses. Through RegXpertPRO , she develops practical tools, frameworks, and advisory support that help pharmaceutical teams make clearer development and submission decisions, build stronger justifications, and prepare more effective regulatory responses.</p></blockquote>

Agilent Technologies: Dissolution Testing — Ask Us Anything

Dissolution Testing — Ask Us Anything

Explore dissolution testing challenges, automation strategies, regulatory updates, and expert guidance in this interactive Dissolution Discussion Group webinar.

<p><strong>Comprehensive toxicological screening requires analytical technologies that combine sensitivity, selectivity, and robustness while keeping pace with an ever‑expanding panel of known and emerging compounds. In this webinar, we will introduce the Xevo™ MRT High Resolution Mass Spectrometer (Multi‑Reflecting Time‑of‑Flight) platform as a powerful solution for broad, high‑confidence toxicology screening.</strong></p><p>We will discuss how the ultra‑high resolving power and mass accuracy of xMRT enable confident identification of drugs, metabolites, and toxic compounds in complex biological matrices and how it reduces false positives in library‑based screening workflows.</p><blockquote><p><strong>Presenter: </strong>Elodie Dubin (Clinical Applications Specialist, Waters Corporation)</p><p>Elodie Dubin, is a Clinical Applications Specialist at Waters Corporation, based at the French facilities near Paris.</p><p>Elodie joined Waters in 2019 as part of the French Demo Lab team, where she supported local customers through system demonstrations, customer training, application setup, and ongoing application support. Since 2022, she has been a member of the EU Clinical Customer Success Team, continuing similar activities with a dedicated focus on clinical customers across Europe.</p><p>Her main areas of expertise include High‑Resolution Mass Spectrometry, which she began working with during her PhD in Analytical Chemistry, as well as Triple Quadrupole technology, for which she regularly supports customers on‑site with application setup and hands‑on training.</p></blockquote>

Waters Corporation: Next-gen HRMS for toxicology and drug labs

Seeing More with Greater Confidence: Next-Generation HRMS for Toxicology Screening

In this webinar, we will introduce the Xevo™ MRT HRMS platform as a powerful solution for broad, high‑confidence toxicology screening.

Related content

Invitation to the ALS Webinar PFAS in Water 2026: Achieving Compliance through Advanced Analytical Strategies

Deoxyribozymes, tools for precision sensing and machine learning-guided discoveries

Scientists Uncover a Tipping Point in Cells. This Is How Cancer May Begin